Skip to main content
Top
Published in: Gastric Cancer 4/2011

Open Access 01-10-2011 | Letter to the Editor

Extended lymph node dissection for gastric cancer from a European perspective

Authors: Johan L. Dikken, Marcel Verheij, Annemieke Cats, Edwin P. M. Jansen, Henk H. Hartgrink, Cornelis J. H. van de Velde

Published in: Gastric Cancer | Issue 4/2011

Login to get access

Excerpt

The extent of lymphadenectomy for the curative treatment of gastric cancer has been subject to considerable debate over the past decades. Despite a plethora of retrospective and single-institution studies comparing different types of lymphadenectomy, only a limited number of randomized controlled trials have focused on this subject. Recently, Tanizawa et al. [1] published an extensive review of existing evidence on lymph node dissection in gastric cancer. This comprehensive review discusses several aspects of lymphadenectomy, including limited versus extended lymphadenectomy, dissection of para-aortal lymph nodes, routine splenectomy and pancreatectomy, and lymph node dissection for early gastric cancer. However, shortly after the review was accepted several relevant and important studies on gastric cancer surgery were published. In the current letter, we wish to give a European perspective on the extent of lymphadenectomy that should be recommended for advanced, resectable gastric cancer, and reflect on several more recent developments. …
Literature
1.
go back to reference Tanizawa Y, Terashima M. Lymph node dissection in the resection of gastric cancer: review of existing evidence. Gastric Cancer. 2010;13(3):137–48.CrossRefPubMed Tanizawa Y, Terashima M. Lymph node dissection in the resection of gastric cancer: review of existing evidence. Gastric Cancer. 2010;13(3):137–48.CrossRefPubMed
2.
go back to reference Bonenkamp JJ, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345(8952):745–8.CrossRefPubMed Bonenkamp JJ, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345(8952):745–8.CrossRefPubMed
3.
go back to reference Cuschieri A, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996;347(9007):995–9.CrossRefPubMed Cuschieri A, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996;347(9007):995–9.CrossRefPubMed
4.
go back to reference Hartgrink HH, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22(11):2069–77.CrossRefPubMed Hartgrink HH, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22(11):2069–77.CrossRefPubMed
5.
go back to reference Songun I, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49.CrossRefPubMed Songun I, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49.CrossRefPubMed
6.
go back to reference Degiuli M, Sasako M, Ponti A. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg. 2010;97(5):643–9.CrossRefPubMed Degiuli M, Sasako M, Ponti A. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg. 2010;97(5):643–9.CrossRefPubMed
7.
go back to reference Krijnen P, et al. Improved survival after resectable non-cardia gastric cancer in The Netherlands: the importance of surgical training and quality control. Eur J Surg Oncol. 2009;35(7):715–20.CrossRefPubMed Krijnen P, et al. Improved survival after resectable non-cardia gastric cancer in The Netherlands: the importance of surgical training and quality control. Eur J Surg Oncol. 2009;35(7):715–20.CrossRefPubMed
8.
go back to reference Birkmeyer JD, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128–37.CrossRefPubMed Birkmeyer JD, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128–37.CrossRefPubMed
9.
go back to reference Jensen LS, et al. Enforcing centralization for gastric cancer in Denmark. Eur J Surg Oncol. 2010;36:S50–4.CrossRefPubMed Jensen LS, et al. Enforcing centralization for gastric cancer in Denmark. Eur J Surg Oncol. 2010;36:S50–4.CrossRefPubMed
10.
go back to reference Birgisson H, et al. Improved survival in cancer of the colon and rectum in Sweden. Eur J Surg Oncol. 2005;31(8):845–53.CrossRefPubMed Birgisson H, et al. Improved survival in cancer of the colon and rectum in Sweden. Eur J Surg Oncol. 2005;31(8):845–53.CrossRefPubMed
11.
go back to reference Macdonald JS, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.CrossRefPubMed Macdonald JS, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.CrossRefPubMed
12.
go back to reference Hundahl SA, et al. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol. 2002;9(3):278–86.CrossRefPubMed Hundahl SA, et al. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol. 2002;9(3):278–86.CrossRefPubMed
13.
go back to reference Dikken JL, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010;28(14):2430–6.CrossRefPubMed Dikken JL, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010;28(14):2430–6.CrossRefPubMed
14.
go back to reference Cunningham D, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMed Cunningham D, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMed
15.
go back to reference Dikken JL, et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer. 2011;11(1):329.CrossRefPubMedPubMedCentral Dikken JL, et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer. 2011;11(1):329.CrossRefPubMedPubMedCentral
Metadata
Title
Extended lymph node dissection for gastric cancer from a European perspective
Authors
Johan L. Dikken
Marcel Verheij
Annemieke Cats
Edwin P. M. Jansen
Henk H. Hartgrink
Cornelis J. H. van de Velde
Publication date
01-10-2011
Publisher
Springer Japan
Published in
Gastric Cancer / Issue 4/2011
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-011-0081-x

Other articles of this Issue 4/2011

Gastric Cancer 4/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.